Compare Gigacloud Technology Inc (GCT) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Mesoblast Limited — how do they compare? Gigacloud Technology Inc trades at $38.02 (market cap $1.40B), while Mesoblast Limited trades at $19.12 (market cap $2.31B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, Gigacloud Technology Inc nearer its low. Which is the better fit depends on your goals.
| GCT | MESO | |
|---|---|---|
Market Cap | $1.40B | $2.31B |
Sector | Technology | Technology |
52-Week High | $51.80 | $20.96 |
52-Week Low | $20.97 | $11.35 |
Enterprise Value | $1.51B | $2.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GigaCloud Technology (GCT) trades at $37.85, up 6.91% with strong earnings momentum after beating Q1 2026 EPS estimates. The stock shows bullish technical signals despite mixed indicators, with valuation ratios appearing attractive (P/E 9.49, P/S 1.02). Recent recognition as TIME's World Growth Leader and expanding international presence highlight operational strength.
GCT presents compelling value with robust profitability (32.14% ROE) and consistent earnings beats, though technical overbought conditions and competitive pressures warrant caution. The 66.7% analyst buy rating supports upside potential, but investors should monitor execution risks in international expansion.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
